Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 1/20 | 0.62 |
| ▸ | PPARA | Q07869 | 3/20 | 0.61 |
| ▸ | PPARG | P37231 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CTSK | P43235 | 3/20 | 0.51 |
| ▸ | TACR1 | P25103 | 2/20 | 0.51 |
| ▸ | MMP13 | P45452 | 2/20 | 0.51 |
| ▸ | CTRB1 | P17538 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.50 |
| ▸ | TDO2 | P48775 | 1/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.49 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1541597 | 1.00 | CASP1 (0.62) | CASP1PPARAPPARGCA2CTSK | |
| SCHEMBL4973400 | 1.00 | CASP1 (0.62) | CASP1PPARAPPARGCA2CTSK | |
| SCHEMBL7810073 | 0.99 | CASP1 (0.61) | CASP1PPARAPPARGCA2CTSK | |
| SCHEMBL7810068 | 0.99 | CASP1 (0.61) | CASP1PPARAPPARGCA2CTSK | |
| SCHEMBL7309224 | 0.90 | PPARA (0.55) | CASP1PPARAPPARGCA2CTSK | |
| SCHEMBL7309215 | 0.90 | PPARA (0.55) | CASP1PPARAPPARGCA2CTSK | |
| SCHEMBL7564546 | 0.89 | KYNU (0.58) | CASP1PPARAPPARGCA2CTSK | |
| SCHEMBL6576404 | 0.89 | KYNU (0.58) | CASP1PPARAPPARGCA2CTSK | |
| SCHEMBL4968729 | 0.89 | KYNU (0.58) | CASP1PPARAPPARGCA2CTSK | |
| SCHEMBL7810070 | 0.88 | CA2 (0.61) | CASP1PPARAPPARGCA2CTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6906224-B2 | Process for producing α-aminoketones | AJINOMOTO CO., INC. (JP) | 2005-06-14 | — | — | US | disclosed |
| US-20040210089-A1 | Process for producing alpha-aminoketones | AJINOMOTO CO., INC. (JP) | 2004-10-21 | — | — | US | disclosed |
| US-6696571-B2 | REACTING A 3-OXAZOLIDIN-5-ONE DERIVATIVE WITH A HALOMETHYL LITHIUM AND THEN TREATING WITH AN ACID | AJINOMOTO CO., INC. (JP) | 2004-02-24 | — | — | US | disclosed |
| EP-1046634-B1 | PROCESSES FOR PRODUCING BETA-HALOGENO-ALPHA-AMINO-CARBOXYLIC ACIDS AND PHENYLCYSTEINE DERIVATIVES AND INTERMEDIATES THEREOF | KANEKA CORP (JP) | 2003-09-10 | — | — | EP | disclosed |
| US-20030100796-A1 | Process for producing alpha-aminoketones | AJINOMOTO CO., INC. (JP) | 2003-05-29 | — | — | US | disclosed |
| US-6570039-B2 | Oxazolidine compounds as chemical intermediates | AJINOMOTO CO., INC. (JP) | 2003-05-27 | — | — | US | disclosed |
| US-20020103399-A1 | Processes for producing B-halogeno-a-amino-carboxylic acids and phenylcysteine derivatives and intermediates thereof | YAMASHITA KOKI (JP) | 2002-08-01 | — | — | US | disclosed |
| US-20020082450-A1 | Processes for producing B-halogeno-a-amino-carboxylic acids and phenylcysteine derivatives and intermediates thereof | YAMASHITA KOKI (JP) | 2002-06-27 | — | — | US | disclosed |
| US-6372941-B1 | HALOGENATING HYDROXYL GROUP OF BETA-HYDROXY-ALPHA-AMINOCARBOXYLIC ACID OR ACID SALT THEREOF BY TREATING WITH HALOGENATING AGENT IN ETHER SOLVENT | KANEKA CORPORATION (JP) | 2002-04-16 | — | — | US | disclosed |
| US-20020035288-A1 | Process for producing alpha-aminoketones | AJINOMOTO CO., INC. (JP) | 2002-03-21 | — | — | US | disclosed |
| EP-1046634-A1 | PROCESSES FOR PRODUCING BETA-HALOGENO-ALPHA-AMINO-CARBOXYLIC ACIDS AND PHENYLCYSTEINE DERIVATIVES AND INTERMEDIATES THEREOF | KANEKA CORPORATION (JP) | 2000-10-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103399-A1 | Processes for producing B-halogeno-a-amino-carboxylic acids and phenylcysteine derivatives and intermediates thereof | BCAT1, CBS, BCAT2 | CASP1 2024/4885PPARA 243/4885PPARG 198/4885 |
| US-20040210089-A1 | Process for producing alpha-aminoketones | AAAS, BCKDK, KHK | CASP1 1505/4885PPARA 2150/4885PPARG 2853/4885 |
| US-20020035288-A1 | Process for producing alpha-aminoketones | AAAS, BCKDK, KHK | CASP1 1505/4885PPARA 2150/4885PPARG 2853/4885 |
| US-20020082450-A1 | Processes for producing B-halogeno-a-amino-carboxylic acids and phenylcysteine derivatives and intermediates thereof | BCAT1, CBS, BCAT2 | CASP1 2024/4885PPARA 243/4885PPARG 198/4885 |
| US-20030100796-A1 | Process for producing alpha-aminoketones | AAAS, BCKDK, KHK | CASP1 1505/4885PPARA 2150/4885PPARG 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.